Clinical Trial: Biomarkers in Giant Cells Arteritis
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Biomarkers in Giant Cells Arteritis
Brief Summary:
Giant cells arteritis or Horton disease is a vasculitis that affects great vessels. This is the most frequent vasculitis of the population over the age of 50. This vasculitis is at the origin of an inflammatory infiltrate of arterial tunics, essentially composed of lymphocytes. Clinical signs are a deterioration of general state, unusual cephalgias, jaw pain, scalp hyperesthesia, but can also be serious ischemic complication, especially ophthalmologic with the possibility to go blind. Until now, the standard treatment is a high dosage corticosteroid therapy.
Diagnosis is based on criterias of the American College of Rheumatology, dating back to 1990. The relapse rate is important, ranging from 10 to 64 % according to studies. There are also issues of becoming dependent on steroid.
So it is important to determine new diagnosis markers and a therapeutic following of giant cells arteritis.
With this study several biomarkers of inflammation will be studied in order to determine if one ore many of them have a good sensitivity and special feature for diagnosis and following of giant cells arteritis.
The main goal is to determine a new diagnosis marker for giant cells arteritis.
Detailed Summary:
Sponsor: University Hospital, Grenoble
Current Primary Outcome: Biomarkers's serum sampling [ Time Frame: 3 minutes ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University Hospital, Grenoble
Dates:
Date Received: July 20, 2016
Date Started: October 2015
Date Completion: October 2019
Last Updated: July 22, 2016
Last Verified: July 2016